Vor Biopharma is developing telitacicept, an investigational treatment for autoimmune diseases. It last closed at $18.18 on Nov 17, down 4.16% on the day.
VOR · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 7% below its 20 day and 9% below its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Oct 7) at $17.86, and the nearest resistance the Pivot at $18.33.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$26.0052 week high+43.0%
$20.55100 day average+13.0%
$19.79Swing high (Oct 21)+8.9%
$19.7350 day average+8.5%
$19.4320 day average+6.9%
$18.89Pivot R1+3.9%
$18.33Pivot+0.8%
$18.18Last close
$17.86Swing low (Oct 7)−1.8%
$17.62Pivot S1−3.1%
$17.59200 day average−3.2%
$6.5052 week low−64.2%
Indicators
RSI (14)
41.71
Middle of its range
Neutral
MACD
-0.16
Below its signal line
Bearish
Stochastic
23.5
Middle of its range
Neutral
ADX (14)
9.2
No clear trend
Williams %R
-89.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-131.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−8.5%
Change over 10 sessions
Bearish
ATR (14)
$1.22
Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Moving sideways
Short trendNeutral
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityLow, 16.6%/day
Key levels
$26.0052 week high+43.0%
$20.55100 day average+13.0%
$19.79Swing high (Oct 21)+8.9%
$19.7350 day average+8.5%
$19.4320 day average+6.9%
$18.89Pivot R1+3.9%
$18.33Pivot+0.8%
$18.18Last close
$17.86Swing low (Oct 7)−1.8%
$17.62Pivot S1−3.1%
$17.59200 day average−3.2%
$6.5052 week low−64.2%
Indicators
RSI (14)
47.20
Middle of its range
Neutral
MACD
0.28
Below its signal line
Bearish
Stochastic
19.3
Near the bottom of its range
Oversold
ADX (14)
27.7
Trending up
Williams %R
-92.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-68.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−18.5%
Change over 10 sessions
Bearish
ATR (14)
$3.02
Typical daily range, 16.6% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200–
What happened before, for VOR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how VOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow VOR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VOR is in one of them and how their past VOR trades turned out.
Vor Biopharma is a biopharmaceutical company based in Boston, Massachusetts, that is developing telitacicept, a treatment for autoimmune diseases. Telitacicept is a fusion protein that acts on two signaling molecules involved in B cell activity, and the company is studying it in conditions such as generalized myasthenia gravis and Sjögren's disease. It holds rights to the drug outside Greater China and is running advanced trials aimed at approval in the United States, Europe and Japan. Its intended users are patients with autoimmune diseases and the doctors who treat them.